<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">47969</article-id><article-id pub-id-type="doi">10.7554/eLife.47969</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Loss of adaptive capacity in asthmatic patients revealed by biomarker fluctuation dynamics after rhinovirus challenge</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-139537"><name><surname>Sinha</surname><given-names>Anirban</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4146-9687</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146929"><name><surname>Lutter</surname><given-names>René</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146928"><name><surname>Xu</surname><given-names>Binbin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146930"><name><surname>Dekker</surname><given-names>Tamara</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146931"><name><surname>Dierdorp</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146932"><name><surname>Sterk</surname><given-names>Peter J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146933"><name><surname>Frey</surname><given-names>Urs</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146934"><name><surname>Eckert</surname><given-names>Edgar Delgado</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Respiratory Medicine</institution>, <institution>Amsterdam University Medical Center, University of Amsterdam</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff2"><institution content-type="dept">Inserm, Bordeaux Population Health Research Center</institution>, <institution>University of Bordeaux</institution>, <addr-line><named-content content-type="city">Bordeaux</named-content></addr-line>, <country>France</country></aff><aff id="aff3"><institution content-type="dept">Department of Experimental Immunology</institution>, <institution>Amsterdam University Medical Center, University of Amsterdam</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff4"><institution>University Children's Hospital, University of Basel</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-41027"><name><surname>van der Meer</surname><given-names>Jos WM</given-names></name><role>Reviewing editor</role><aff><institution>Radboud University Medical Centre</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>a.sinha@amsterdamumc.nl</email> (AS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>11</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e47969</elocation-id><history><date date-type="received"><day>26</day><month>04</month><year>2019</year></date><date date-type="accepted"><day>04</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Sinha et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Sinha et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-47969-v1.pdf"/><abstract><p>Asthma is a dynamic disease, in which lung mechanical and inflammatory processes interact in a complex manner, often resulting in exaggerated physiological, in particular, inflammatory responses to exogenous triggers. We hypothesize that this may be explained by respiratory disease-related systems instability and loss of adaptability to changing environmental conditions, manifested in highly fluctuating biomarkers and symptoms. Using time series of inflammatory (eosinophils, neutrophils, FeNO), clinical and lung function biomarkers (PEF, FVC,FEV<sub>1</sub>), we estimated this loss of adaptive capacity (AC) during an experimental rhinovirus infection in 24 healthy and asthmatic human volunteers. Loss of AC was estimated by comparing similarities between pre- and post-challenge time series. Unlike healthy participants, the asthmatic's post-viral-challenge state resembled more other rhinovirus-infected asthmatics than their own pre-viral-challenge state (hypergeometric-test: p=0.029). This reveals loss of AC and supports the concept that in asthma, biological processes underlying inflammatory and physiological responses are unstable, contributing to loss of control.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>European Respiratory Society-Maria Sklodowska Curie actions Cofund Respire 2</institution></institution-wrap></funding-source><award-id>MCF-7077-2014</award-id><principal-award-recipient><name><surname>Sinha</surname><given-names>Anirban</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Chiesi Pharmaceuticals</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sinha</surname><given-names>Anirban</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The study protocol along with the viral dose used and its safety have been approved by the institutional Medical Ethics Committee in Amsterdam University Medical Centre (Protocol No. NL54293.018.15). The trial has been registered at the Netherlands Trial Register (Netherlands Trial Register (NTR5426/NL5317).Proper Informed Consent was taken from every participant.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-47969-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>